Novartis AG to Discuss the Zolgensma® and Piqray® US FDA Approvals Call Transcript
(technical difficulty)
during the conference. A recording of this conference call, including the Q&A session, will be available on our website shortly after the call ends. (Operator Instructions)
With that, I would like to hand over to Mr. Samir Shah, Global Head of Investor Relation. Please go ahead, sir.
Thank you very much, and thank you to all of you taking the time on a public holiday to actually participate in this conference call. With me, we have Vas Narasimhan, CEO of the group; Paul Hudson, CEO of Pharma; and Dave Lennon, Head of the AveXis group.
The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other factors. These may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Please refer to the company's Form 20-F on file with the U.S. Securities and Exchange Commission for a description of some of these factors.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
